Previous close | 5,578.00 |
Open | 5,600.00 |
Bid | 5,442.00 x N/A |
Ask | 5,450.00 x N/A |
Day's range | 5,420.00 - 5,631.00 |
52-week range | 3,566.00 - 5,656.00 |
Volume | |
Avg. volume | 4,287,095 |
Market cap | 10.449T |
Beta (5Y monthly) | 0.26 |
PE ratio (TTM) | 51.96 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 60.00 (1.08%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.